...October 22, 2019 NEW YORK (S&P Global Ratings) Oct. 22, 2019--S&P Global Ratings today said that it expects Boston Scientific Corp.'s funding of the repurchase of up to $1 billion of its public notes with newly issued debt will be leverage neutral. The ratings, including the '###-' issuer credit rating on the company, remain unchanged, reflecting our expectation that Boston Scientific will generally maintain adjusted debt leverage of less than 3.5x in 2020 and beyond, despite a temporary increase in 2019 leverage to the high-3x after the recent BTG acquisition. We also project the company will generate around $2 billion of annual free operating cash flow in 2019-2020. The rating also reflects the company's strong and stable business, including its broad portfolio of market-leading medical devices used in diverse specialties, its expansive geographic footprint, its limited competition, and the high barriers to entry in these product markets. The positive outlook still reflects our expectation...
